Early trial explores apalutamide for chinese men with advanced prostate cancer
NCT ID NCT03523442
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 24 times
Summary
This early-phase study tests the drug apalutamide in Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. The main goals are to check how the drug moves through the body and to monitor any side effects. Nineteen participants will take a daily 240 mg dose, and researchers will also track changes in PSA levels, a marker of cancer activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital of Peking University
Beijing, 100142, China
-
Fudan Cancer Hospital
Shanghai, 200032, China
-
Jiangsu Cancer Hospital
Nanjing, 210000, China
-
Peking University Third Hospital
Beijing, 100083, China
Conditions
Explore the condition pages connected to this study.